Disposable products developer Merit Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Corvocet biopsy system.
Marking the company's first entry into the biopsy market, Corvocet is designed to obtain core biopsy samples from liver, kidney, prostate, breast, lung, and other soft-tissue tumors, according to Merit. It comes in standalone packaging and also as a component in kits. Corvocet can be used one-handed and includes technology for reducing sound levels, the vendor said.
Merit will showcase Corvocet at next week's Society of Interventional Radiology (SIR) annual meeting in Vancouver, British Columbia. The firm plans to release Corvocet in the U.S. over the next month. Other biopsy devices will be introduced in the future, Merit said.
